17090702|t|A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2.
17090702|a|The effect of ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) on cognitive impairment in mice, previously treated with methamphetamine (METH) at a dose of 1 mg/kg for 7 days, was investigated. ZSET1446 showed a significant ameliorating effect on METH-induced impairment of recognition memory, although it had no effect on exploratory behavior. ZSET1446 (1 microg/kg) recovered the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in the prefrontal cortex (PFC) of METH-treated mice. The compound increased phosphorylated ERK1/2 levels in the hippocampus but not PFC of naive mice without affecting the total ERK1/2 levels. The ameliorating effect of ZSET1446 on recognition memory in METH-treated mice was negated by pretreatment with a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor, SL327 (alpha-[amino-(4-aminophenylthio)methylene]-2-(trifluoromethyl)phenylacetonitrile). Furthermore, the dopamine D1 receptor antagonist, SCH23390 [R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine], and N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 [5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate)], blocked the ameliorating effect of ZSET1446 on METH-induced memory impairment, whereas the D2 receptor antagonist, raclopride, had no effect. These results suggest that the ameliorative effect of ZSET1446 on METH-induced memory impairment is associated with indirect activation of ERK1/2 following stimulation with dopamine D1 and NMDA receptors of the PFC. ZSET1446 would be a potential candidate for further preclinical study aimed at the treatment of cognitive deficits in Alzheimer's disease and schizophrenia, as well as METH psychosis.
17090702	8	23	azaindolizinone	Chemical	-
17090702	35	43	ZSET1446	Chemical	MESH:C511224
17090702	45	94	spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one	Chemical	MESH:C511224
17090702	105	120	methamphetamine	Chemical	MESH:D008694
17090702	129	161	impairment of recognition memory	Disease	MESH:D008569
17090702	165	169	mice	Species	10090
17090702	184	225	extracellular signal-regulated kinase 1/2	Gene	26417;26413
17090702	241	249	ZSET1446	Chemical	MESH:C511224
17090702	251	300	spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one	Chemical	MESH:C511224
17090702	305	325	cognitive impairment	Disease	MESH:D003072
17090702	329	333	mice	Species	10090
17090702	359	374	methamphetamine	Chemical	MESH:D008694
17090702	376	380	METH	Chemical	MESH:D008694
17090702	433	441	ZSET1446	Chemical	MESH:C511224
17090702	486	490	METH	Chemical	MESH:D008694
17090702	499	531	impairment of recognition memory	Disease	MESH:D008569
17090702	584	592	ZSET1446	Chemical	MESH:C511224
17090702	665	706	extracellular signal-regulated kinase 1/2	Gene	26417;26413
17090702	708	714	ERK1/2	Gene	26417;26413
17090702	750	754	METH	Chemical	MESH:D008694
17090702	763	767	mice	Species	10090
17090702	807	813	ERK1/2	Gene	26417;26413
17090702	861	865	mice	Species	10090
17090702	894	900	ERK1/2	Gene	26417;26413
17090702	936	944	ZSET1446	Chemical	MESH:C511224
17090702	970	974	METH	Chemical	MESH:D008694
17090702	983	987	mice	Species	10090
17090702	1112	1117	SL327	Chemical	MESH:C424127
17090702	1119	1199	alpha-[amino-(4-aminophenylthio)methylene]-2-(trifluoromethyl)phenylacetonitrile	Chemical	-
17090702	1219	1239	dopamine D1 receptor	Gene	13488
17090702	1252	1260	SCH23390	Chemical	MESH:C534628
17090702	1262	1340	R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine	Chemical	-
17090702	1396	1402	MK-801	Chemical	MESH:D016291
17090702	1404	1441	5H-dibenzo[a,d]cyclohepten-5,10-imine	Chemical	-
17090702	1443	1462	dizocilpine maleate	Chemical	MESH:D016291
17090702	1501	1509	ZSET1446	Chemical	MESH:C511224
17090702	1513	1517	METH	Chemical	MESH:D008694
17090702	1526	1543	memory impairment	Disease	MESH:D008569
17090702	1557	1568	D2 receptor	Gene	13489
17090702	1581	1591	raclopride	Chemical	MESH:D020891
17090702	1662	1670	ZSET1446	Chemical	MESH:C511224
17090702	1674	1678	METH	Chemical	MESH:D008694
17090702	1687	1704	memory impairment	Disease	MESH:D008569
17090702	1747	1753	ERK1/2	Gene	26417;26413
17090702	1824	1832	ZSET1446	Chemical	MESH:C511224
17090702	1920	1938	cognitive deficits	Disease	MESH:D003072
17090702	1942	1961	Alzheimer's disease	Disease	MESH:D000544
17090702	1966	1979	schizophrenia	Disease	MESH:D012559
17090702	1992	1996	METH	Chemical	MESH:D008694
17090702	1997	2006	psychosis	Disease	MESH:D011618
17090702	Negative_Correlation	MESH:C511224	MESH:D008569
17090702	Negative_Correlation	MESH:C534628	13488
17090702	Negative_Correlation	MESH:C511224	MESH:C534628
17090702	Negative_Correlation	MESH:D020891	13489
17090702	Association	MESH:D008694	26413
17090702	Positive_Correlation	MESH:D008694	MESH:D008569
17090702	Negative_Correlation	MESH:C534628	MESH:D008694
17090702	Association	MESH:D008694	26417
17090702	Association	MESH:D016291	MESH:D008569
17090702	Positive_Correlation	MESH:C511224	26417
17090702	Positive_Correlation	MESH:D008694	MESH:D003072
17090702	Negative_Correlation	MESH:C424127	MESH:C511224
17090702	Positive_Correlation	MESH:C511224	26413
17090702	Negative_Correlation	MESH:C511224	MESH:D003072
17090702	Negative_Correlation	MESH:C511224	MESH:D008694
17090702	Negative_Correlation	MESH:C534628	MESH:D008569
17090702	Cotreatment	MESH:C511224	MESH:D016291

